Teva launches generic Actiq

NORTH WALES, Pa. — Teva Pharmaceuticals on Wednesday announced the launch of its new generic of Actiq (fentanyl citrate) oral transmucosal lozenges.

 

The lozenges are indicated to manage breakthrough pain in cancer patients 16 years old and older who are currently receiving and tolerating around-the-clock opioid medicine. They are contraindicated in patients who are not tolerant of opioids, management of acute or postoperative pain and patients sensitive to any of the drug’s ingredients.  

 

Teva’s lozenges will be available in 200-, 400-, 600-, 800-, 1200-, and 1600-mcg dosage strengths.